Valion Bio (VBIO) Cash from Financing Activities (2021 - 2025)

Valion Bio has reported Cash from Financing Activities for 5 years, with the latest figure at $11.6 million in Q4 2025.

• On a quarterly basis, Cash from Financing Activities rose 887.35% year-over-year to $11.6 million in Q4 2025; TTM through Dec 2025 was $18.3 million, a 323.52% increase from a year earlier, with the FY2025 full-year figure at $18.3 million, up 323.52% from the prior year.
• Cash from Financing Activities was $11.6 million for Q4 2025 at Valion Bio, up from $4.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $14.9 million in Q4 2021, with the low at -$584000.0 in Q4 2022.
• Average Cash from Financing Activities over 5 years is $3.0 million, with a median of $1.4 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities slumped 103.92% in 2022, then surged 7627.27% in 2024.
• Over 5 years, Cash from Financing Activities stood at $14.9 million in 2021, then plunged by 103.92% to -$584000.0 in 2022, then surged by 850.17% to $4.4 million in 2023, then slumped by 73.11% to $1.2 million in 2024, then surged by 887.35% to $11.6 million in 2025.
• The last three Cash from Financing Activities figures came in at $11.6 million (Q4 2025), $4.3 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.